Cargando…

Effects of imiglucerase on the growth and metabolism of Gaucher disease type I patients: a systematic review

BACKGROUND: Gaucher disease (GD) type I is the most common type of GD. Its main clinical manifestations are hepatosplenomegaly as well as bone and hematological abnormalities. The objective of the present study was to perform a literature review on the growth and metabolism of GD type I patients. ME...

Descripción completa

Detalles Bibliográficos
Autores principales: Doneda, Divair, Netto, Cristina B, Moulin, Cileide C, Schwartz, Ida Vanessa D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3630065/
https://www.ncbi.nlm.nih.gov/pubmed/23570288
http://dx.doi.org/10.1186/1743-7075-10-34
_version_ 1782266649844383744
author Doneda, Divair
Netto, Cristina B
Moulin, Cileide C
Schwartz, Ida Vanessa D
author_facet Doneda, Divair
Netto, Cristina B
Moulin, Cileide C
Schwartz, Ida Vanessa D
author_sort Doneda, Divair
collection PubMed
description BACKGROUND: Gaucher disease (GD) type I is the most common type of GD. Its main clinical manifestations are hepatosplenomegaly as well as bone and hematological abnormalities. The objective of the present study was to perform a literature review on the growth and metabolism of GD type I patients. METHODS: We searched Pubmed and Scielo.br databases with predetermined study limits: case series (n≥5), clinical trials, systematic reviews, and meta-analyses, and enzyme replacement therapy (ERT) with alglucerase or imiglucerase. The outcomes of interest were the following: growth and development, weight, height, malnutrition, overweight, obesity, basal metabolism, hypermetabolism, insulin resistance, and diabetes. A total of 175 articles were found, of which 28 met the inclusion criteria; these articles were grouped into three central themes: 1) growth of children and adolescents before and after ERT; 2) metabolic changes that remained during ERT; and 3) changes in metabolic status resulting from the treatment. RESULTS AND DISCUSSION: The articles included in the present literature review are very heterogeneous, which hinders the analysis of data. They indicated that GD patients usually show low weight and height before ERT, which are improved with treatment in children and adolescents. Studies evaluating the energy metabolism by indirect calorimetry have indicated that the disease is associated with hypermetabolism. In adults, some changes in energy metabolism remain on ERT, and alterations, such as insulin resistance, seem to be associated with the treatment. It is not clear which are the required doses of imiglucerase for obtaining an adequate cost-effective relation, as well as the advisable therapeutic measures to avoid possible long-term adverse effects related to ERT. CONCLUSIONS: ERT tends to normalise the growth of children and adolescents with GD type I, it seems to cause a partial response in relation to some metabolic changes associated with the disease, and it can causes metabolic changes such as weight gain in adult patients. Therefore, additional research is necessary.
format Online
Article
Text
id pubmed-3630065
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-36300652013-04-19 Effects of imiglucerase on the growth and metabolism of Gaucher disease type I patients: a systematic review Doneda, Divair Netto, Cristina B Moulin, Cileide C Schwartz, Ida Vanessa D Nutr Metab (Lond) Review BACKGROUND: Gaucher disease (GD) type I is the most common type of GD. Its main clinical manifestations are hepatosplenomegaly as well as bone and hematological abnormalities. The objective of the present study was to perform a literature review on the growth and metabolism of GD type I patients. METHODS: We searched Pubmed and Scielo.br databases with predetermined study limits: case series (n≥5), clinical trials, systematic reviews, and meta-analyses, and enzyme replacement therapy (ERT) with alglucerase or imiglucerase. The outcomes of interest were the following: growth and development, weight, height, malnutrition, overweight, obesity, basal metabolism, hypermetabolism, insulin resistance, and diabetes. A total of 175 articles were found, of which 28 met the inclusion criteria; these articles were grouped into three central themes: 1) growth of children and adolescents before and after ERT; 2) metabolic changes that remained during ERT; and 3) changes in metabolic status resulting from the treatment. RESULTS AND DISCUSSION: The articles included in the present literature review are very heterogeneous, which hinders the analysis of data. They indicated that GD patients usually show low weight and height before ERT, which are improved with treatment in children and adolescents. Studies evaluating the energy metabolism by indirect calorimetry have indicated that the disease is associated with hypermetabolism. In adults, some changes in energy metabolism remain on ERT, and alterations, such as insulin resistance, seem to be associated with the treatment. It is not clear which are the required doses of imiglucerase for obtaining an adequate cost-effective relation, as well as the advisable therapeutic measures to avoid possible long-term adverse effects related to ERT. CONCLUSIONS: ERT tends to normalise the growth of children and adolescents with GD type I, it seems to cause a partial response in relation to some metabolic changes associated with the disease, and it can causes metabolic changes such as weight gain in adult patients. Therefore, additional research is necessary. BioMed Central 2013-04-09 /pmc/articles/PMC3630065/ /pubmed/23570288 http://dx.doi.org/10.1186/1743-7075-10-34 Text en Copyright © 2013 Doneda et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Doneda, Divair
Netto, Cristina B
Moulin, Cileide C
Schwartz, Ida Vanessa D
Effects of imiglucerase on the growth and metabolism of Gaucher disease type I patients: a systematic review
title Effects of imiglucerase on the growth and metabolism of Gaucher disease type I patients: a systematic review
title_full Effects of imiglucerase on the growth and metabolism of Gaucher disease type I patients: a systematic review
title_fullStr Effects of imiglucerase on the growth and metabolism of Gaucher disease type I patients: a systematic review
title_full_unstemmed Effects of imiglucerase on the growth and metabolism of Gaucher disease type I patients: a systematic review
title_short Effects of imiglucerase on the growth and metabolism of Gaucher disease type I patients: a systematic review
title_sort effects of imiglucerase on the growth and metabolism of gaucher disease type i patients: a systematic review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3630065/
https://www.ncbi.nlm.nih.gov/pubmed/23570288
http://dx.doi.org/10.1186/1743-7075-10-34
work_keys_str_mv AT donedadivair effectsofimigluceraseonthegrowthandmetabolismofgaucherdiseasetypeipatientsasystematicreview
AT nettocristinab effectsofimigluceraseonthegrowthandmetabolismofgaucherdiseasetypeipatientsasystematicreview
AT moulincileidec effectsofimigluceraseonthegrowthandmetabolismofgaucherdiseasetypeipatientsasystematicreview
AT schwartzidavanessad effectsofimigluceraseonthegrowthandmetabolismofgaucherdiseasetypeipatientsasystematicreview